Renal vasodilating and diuretic actions of a selective endothelin ETB receptor agonist, IRL1620.
The effects of a selective agonist for endothelin ETB receptors, Suc-[Glu9,Ala11,15]endothelin-1-(8-21), IRL1620, on renal hemodynamics and urine formation were studied in anesthetized dogs. Intrarenal arterial infusion of IRL1620 at a dose of 50 ng/kg/min increased renal blood flow from 3.37 +/- 0.30 (mean +/- S.E.) to a maximal value of 4.43 +/- 0.45 ml/g kidney weight per min (ml/g/min) at 9.1 +/- 1.0 min after the start of infusion, with no change in systemic blood pressure and heart rate. Urine flow rate increased and urine osmolality, osmolar clearance and free water reabsorption decreased significantly whereas glomerular filtration rate remained unchanged. In dogs given ibuprofen (12.5 mg/kg, i.v.) after the start of infusion of the peptide, renal blood flow increased slightly but significantly from 3.78 +/- 0.82 to 4.17 +/- 0.96 ml/g/min (1.0 +/- 0.1 min), followed by a gradual reduction in renal blood flow. In dogs given L-NG-nitroarginine (75 micrograms/kg/min), the renal blood flow decreased following intrarenal administration of IRL1620 (50 ng/kg/min). It is suggested that IRL1620 enhances the release of nitric oxide and prostaglandins in the kidney and promotes renal vasodilation. The IRL1620-induced reduction of urine osmolality and free water reabsorption was affected by neither ibuprofen nor L-NG-nitroarginine, thereby suggesting that the suppression of urine concentration did not seem to be linked to the enhanced production of nitric oxide or prostaglandins in the kidney.
Yukimura
T
T
Department of Pharmacology, Osaka City University Medical School, Japan.
Yamashita
Y
Y
Miura
K
K
Kim
S
S
Iwao
H
H
Takai
M
M
Okada
T
T
D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D004231:Diuresis / Q000187:drug effects*; D004285:Dogs; D016232:Endothelins / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007052:Ibuprofen / Q000008:administration & dosage / Q000494:pharmacology; D007261:Infusions, Intra-Arterial; D007275:Injections, Intravenous; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology; D008297:Male; D019335:Nitroarginine; D009994:Osmolar Concentration; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D017466:Receptors, Endothelin / Q000819:agonists*; D012079:Renal Circulation / Q000187:drug effects; D014554:Urination / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*
D016232:Endothelins; D010446:Peptide Fragments; D017466:Receptors, Endothelin; C074308:sovateltide; D019335:Nitroarginine; D001120:Arginine; D007052:Ibuprofen